
==== Front
Sports Med Health Sci
Sports Med Health Sci
Sports Medicine and Health Science
2666-3376
Chengdu Sport University

S2666-3376(24)00027-1
10.1016/j.smhs.2024.02.007
Review
Current knowledge about pyruvate supplementation: A brief review
Olek Robert A. olek@awf.poznan.pl
a⁎
Kujach Sylwester b
Radak Zsolt cd
a Department of Athletics, Strength, and Conditioning, Poznan University of Physical Education, Poznan, Poland
b Department of Neurophysiology, Neuropsychology and Neuroinformatics, Medical University of Gdansk, Gdansk, Poland
c Research Institute of Sport Science, Hungarian University of Sport Science, Budapest, Hungary
d Faculty of Sport Sciences, Waseda University, Tokorozawa, Japan
⁎ Corresponding author. Department of Athletics, Strength, and Conditioning, Poznan University of Physical Education, Krolowej Jadwigi 27/39; 61-871, Poznan, Poland olek@awf.poznan.pl
28 2 2024
12 2024
28 2 2024
6 4 295301
13 10 2023
19 2 2024
22 2 2024
© 2024 Chengdu Sport University. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.
2024
Chengdu Sport University
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Pyruvate is a three-carbon ketoacid that occurs naturally in cells. It is produced through enzymatic reactions in the glycolytic pathway and plays a crucial role in energy metabolism. Despite promising early results, later well-controlled studies of physically active people have shown that pyruvate supplementation lasting more than 1 week has no ergogenic effects. However, some data suggest that ingested pyruvate may be preferentially metabolized without accumulation in the bloodstream. Pyruvate exhibits antioxidant activity and can affect the cellular redox state, and exogenous pyruvate can influence metabolism by affecting the acid-base balance of the blood. This brief review focuses on the potential effects of pyruvate as a supplement for active people. The current state of understanding suggests that studies of the effects of pyruvate supplementation should prioritize investigating the timing of pyruvate intake.

Keywords

Acidosis
Bicarbonate
Lactate
Nicotinamide adenine dinucleotide
Sirtuins
==== Body
pmcAbbreviation list

AD Alzheimer disease

ALA alanine

BDNF brain-derived neurotrophic factor

CaPYR calcium pyruvate

d days

EtPYR ethyl pyruvate

GPT glutamate-pyruvate transaminase

GSH glutathione

GSSG glutathione disulfide

ip intraperitoneally

iv intravenously

LA lactate

LDH lactate dehydrogenase

ME malic enzyme

NAD+ nicotinamide adenine dinucleotide

NADH nicotinamide adenine dinucleotide reduced form

NADPH nicotinamide adenine dinucleotide phosphate reduced form

NaPYR sodium pyruvate

OAA oxaloacetate

PYR pyruvate

sc subcutaneously

SIRTs sirtuins - NAD-dependent mitochondrial deacetylases family

TCA tricarboxylic acid

V˙O2max maximal oxygen consumption

wk weeks

1 Introduction

Pyruvate (PYR) plays an important role in the major mammalian metabolic pathways. PYR occupies a central position between the catabolic and anabolic pathways involved in the metabolism of carbohydrates, fats, and amino acids (for details see1,2). A closer examination of these pathways indicates that, in most cases, PYR enters the mitochondria before further metabolism. Within mitochondria, PYR may be converted by the pyruvate dehydrogenase complex to acetyl-CoA, which can enter the tricarboxylic acid (TCA) cycle, or it may serve as the starting point for the synthesis of long chain fatty acids, steroids, and ketone bodies. PYR may be used to produce alanine (ALA) via the action of glutamate-pyruvate transaminase (GPT), and may thus play an important role in maintaining the levels of the TCA cycle intermediate, α-ketoglutarate. In the cytoplasm, PYR can be reduced to lactate (LA) via LA dehydrogenase (LDH) or to malate via decarboxylating malate dehydrogenase (malic enzyme: ME). In both cases, the reduced form of nicotinamide adenine dinucleotide (NADH) is oxidized to NAD+. Therefore, PYR may affect the NADH/NAD+ ratio.

2 Effects of prolonged PYR supplementation on body weight and composition

The research findings from studies of PYR supplementation as a weight loss aid are summarized in Table 1. The first studies by Stanko et al.,3, 4, 5, 6 showed that prolonged PYR supplementation decreased body weight by significantly reducing body fat mass. These studies, used high doses of PYR (16–53 ​g/d) along with dihydroxyacetone and/or energy restriction.3, 4, 5, 6 Subsequent studies have examined lower doses of PYR supplementation (2–10 ​g/d) and found conflicting results.7,8 The meta-analysis of six randomized clinical trials showed that PYR was not consistently effective in reducing body weight.9 Two of the studies that found PYR supplementation to be ineffective involved trained athletes who had low body fat composition at the start of the study (15.7% for American football players10 and 8.8% for soccer players11), and fat loss is unlikely to occur in such lean active people. After excluding the studies involving athletes, we observed inverse relationship between the changes in fat loss and the daily PYR dose (Fig. 1). Because PYR may accelerate fatty acid synthesis through acetyl-CoA, excessive PYR intake may be ineffective in promoting fat loss.Table 1 Main results of PYR supplementation on weight loss studies.

Table 1participants female/male
age	intervention	period (days)	pyruvate form	average pyruvate dose (g/d)	placebo	body mass change
in pyruvate group (kg)	body mass change
in placebo group (kg)	difference between changes in body mass	Ref. #	
obese 14/0
not reported	confined to bed
1 015 ​kcal/day	21	20 ​g NaPYR
+16 ​g CaPYR	36	iso-energetically polyglucose	−5.9 ​± ​0.7	−4.3 ​± ​0.3	−1.6 ​kg p ​< ​0.05	3	
obese 13/0
PYR 48.4 ​± ​3.2
PLA 48.7 ​± ​4.9	confined to bed
501 ​kcal/day	21	10 ​g NaPYR
+9 ​g CaPYR
+ 12 ​g DHAP	19	iso-energetically polyglucose	−6.5 ​± ​0.3	−5.6 ​± ​0.2	−0.9 ​kg p ​< ​0.05	4	
hyperlipidemic patients 31/9
PYR 56.3 ​± ​2.5
PLA 54.8 ​± ​2.8	high-fat anabolic (26.3–28.7 ​kcal/kg/day) diet	42	18.8–30 ​g NaPYR
+16.8–23 ​g CaPYR	44.5	iso-energetically polyglucose	0.6 ​± ​0.2	0.7 ​± ​0.2	−0.1 ​kg
N.S.	5	
hyperlipidemic patients 25/9
PYR 58 ​± ​3
PLA 56 ​± ​3	low-cholesterol (21.5 ​kcal/kg/day) diet	42	14–28 ​g NaPYR
+13–25 ​g CaPYR	40	iso-energetically polyglucose	−0.7 ​± ​0.2	−0.1 ​± ​0.2	−0.6 ​kg p ​< ​0.05	6	
healthy BMI >25 16/20
PYR 37.1 ​± ​3.2
PLA 35.6 ​± ​2.5	2 000 ​kcal/day
+45min exercise (3/wk)	42	6 ​g
NaPYR
+ CaPYR	6	maltodextrin	not reported	not reported	N.S.	12	
healthy BMI >25 16/10
PYR 36.5 ​± ​3.0
PLA 39.9 ​± ​3.8	2 000 ​kcal/day
+ 45min exercise (3/wk)	42	6 ​g	6	maltodextrin	−1.2	0.0	−1.2 ​kg
N.D.	7	
moderately overweight untrained 23/0
33 ​± ​8	resistance training 3/wk, walking 30min. 3/wk	30	10 ​g
CaPYR	10	CaCO3 maltodextrindextrose	0.3	1.2	−0.9 ​kg p ​< ​0.05	8	
American football players 0/22
PYR 18.6 ​± ​0.6
PLA 18.3 ​± ​0.4	weight training (3/wk)
football practice (2–3/wk)	35	0.22 ​g/kg CaPYR	19	silica	0.0	0.0	0.0 ​kg
N.S.	10	
soccer players 0/22
PYR 22.5 ​± ​2.3
PLA 21.9 ​± ​3.1	specific training program	28	2 ​g	2	cellulose	−1.1	−0.7	−0.4 ​kg
N.S.	11	
PYR – pyruvate; PLA – placebo; NaPYR – sodium pyruvate; CaPYR – calcium pyruvate; DHAP – dihydroxyacetone phosphate; N.S. – not significant; N.D. – not determined.

Fig. 1 Daily dose of PYR supplementation effect on body fat loss. ( ​× ​) studies on athletes with low body fat content excluded from the analysis; dotted lines represent 95% confidence interval.

Fig. 1

3 Supplementation and exercise performance

The first studies of PYR supplementation and exercise performance were also conducted by Stanko et al.13,14 These authors found improvements in aerobic endurance capacity after PYR supplementation, possibly as a result of an increased rate of muscle glucose uptake and sparing of muscle glycogen. However, these studies involved untrained participants who consumed 25 ​g of PYR per day combined with 75 ​g dihydroxyacetone. Later studies reported different results.10,15,16 In one study, 5 weeks of PYR supplementation (0.22 ​g/kg/d) during the training program of American football players did not improve maximal strength, cycle ergometer peak power, and static vertical jump power output.10 Similarly, 2 weeks of PYR supplementation (8.1 ​g/d) did not improve the ability to maintain power output without fatigue, which is defined as critical power.15 In another study, 1 week of PYR supplementation (7 ​g/d) did not influence the time to exhaustion during exercise performed at 75%–80% V˙O2max in highly trained cyclists (V˙O2max [62.3 ​± ​3.3] ​ml O2/kg/min.).16 These findings have led to a loss of interest in PYR supplementation by athletes.17

A recent study reported higher blood pH, bicarbonate level, and base excess, as well as improved performance during high-intensity interval exercise after PYR supplementation. The study involved male soccer players aged (20 ​± ​2) years (body fat 13.1% ​± ​3.5%) with at least 5 years of training experience and V˙O2max (55.9 ​± ​5.4) ​ml/kg/min of O2.18 The supplementation protocol lasted for 1 week and the dose was 0.1 ​g/kg/d, which provides about 7 ​g/d of PYR.18 One major difference in the supplementation protocol may explain the differences in results between this study and those mentioned above: on day 7 of the more recent study, the entire daily dose was ingested at least 60 ​min before the exercise test started.18 It is possible that the timing of PYR intake is a crucial variable, this point was not considered in the previous studies.10,13, 14, 15

4 Single-dose PYR ingestion

Morrison et al.16 measured whole-blood and plasma PYR levels for the 4-h period following various single-dose PYR consumption and found no effect of 7, 15, and 25 ​g of PYR. The inability to detect any elevation of PYR level in the blood, as well as increased borborygmus and ﬂatulence in subjects consuming higher doses of PYR, led the authors to the speculation that PYR may be decarboxylated in the gastrointestinal tract or eliminated through the feces, and not delivered into muscle cells.16

Supplemental PYR may be absorbed by the intestinal epithelium and transported via the portal vein to the liver, where hepatocytes may utilize PYR for gluconeogenesis,19 which would not affect circulating PYR levels. Blood glucose level is also not significantly affected by various PYR doses.16 However, in another study, an increase in the resting respiratory exchange ratio 3 ​h after a single oral intake of PYR suggested greater carbohydrate oxidation.20 In addition, the increase in plasma free fatty acid level observed in placebo was attenuated 3 ​h after acute ingestion of 7 ​g of PYR20 and 4 ​h after intake of 25 ​g of PYR compared with the 7 ​g dose.16 These findings suggest that PYR may be used as a preferential energy source in the human body without increasing blood PYR levels.

The rate-limiting step of citrate formation in the TCA cycle is the low concentration of oxaloacetate (OAA) in mitochondria,21 and it is possible that PYR could be used to replenish mitochondrial OAA levels. In nonmuscle cells, PYR can be carboxylated to OAA, and may play a role in the muscles in supporting OAA formation by the generation of greater α-ketoglutarate concentration via GPT (Fig. 2).1 Intravenous PYR infusion increases the levels of TCA cycle intermediates, mainly malate, in skeletal muscles.22Fig. 2 Hypothetical metabolism of exogenous PYR at rest; PYR – pyruvate; ALA – alanine; GLU – glutamate; KG –-ketoglutarate; GPT – glutamate-pyruvate transaminase; OAA – oxaloacetate; AcCoA – acetylCoA; PDH – pyruvate dehydrogenase; TCA – tricarboxylic acid cycle; MCT – monocarboxylate transporter.

Fig. 2

The uptake of PYR by cells depends on the monocarboxylate transporter system.23 This system is located in the plasma membrane and transports monocarboxylates together with H+ (Fig. 2), which may indirectly spare blood bicarbonate and increase blood pH.24 Because of sodium-coupled transport, the effects of sodium PYR (NaPYR) differ from those of calcium PYR (CaPYR) in terms of their alkalosis-inducing effects.20 The buffering property of NaPYR has been described in an intravenous infusion study,25 although intravenous PYR infusion has been found to be ineffective in increasing muscle PYR content.22 Moreover, single oral PYR intake causes an increase in blood pH, bicarbonate level, and base excess.20,26

A recently reported PYR supplementation protocol did not modify aerobic energy contributions during high-intensity interval exercises,18 a finding that agrees with previously published results.16 In the recent study, no changes were observed in the contributions of glycolytic energy after PYR supplementation despite modification of the blood buffering capacity. Interestingly, PYR supplementation improved phosphagen energy system regeneration during four sessions of 1-min cycling at 110% Wmax, interspersed with 1 min recovery periods, and six sessions of 6 s maximal cycling sprints, interspersed with 24 s passive recovery periods.18 In addition, peak power output and mean power output increased. Although, supraphysiological PYR concentration in a perfusing solution increases phosphagen levels and improves contractile properties of stressed myocardium,27 there is no evidence that oral PYR supplementation, even in the form of creatine-PYR, affects muscle creatine content and/or performance10,15 (this topic has been reviewed in detail elsewhere28,29). Therefore, it has been suggested that improved exercise performance may be achieved by increased phosphocreatine resynthesis and muscle contraction through a decrease in H+ concentration.18 However, PYR supplementation at a higher dose, and for a longer period does not improve explosive power,10 or delay fatigue.15 The resulting differences between studies may be explained by alkalization induced by a PYR dose ingested 60 ​min before the exercise tests.18 Alternatively, different forms of PYR may also explain resulting differences between studies. For example, NaPYR supplementation at a dose of 0.10 ​g/kg/d for 1 week is ergogenic,18 whereas CaPYR at a dose of 0.22 ​g/kg/d for 5 weeks is not,10 possibly because of the different alkalosis-inducing effects.20

5 Redox state modulation

The nonenzymatic reaction of PYR with hydrogen peroxide was described more than 100 years ago,30 as follows:CH3COCOO− ​+ ​H2O2 → CH3COO− ​+ ​CO2 ​+ ​H2O

Later studies confirmed the PYR antioxidant properties in various models31, 32, 33, 34 and indicated the direct scavenging potential toward peroxynitrite,35 hydroxyl radical,36 and superoxide anion radical.37 In addition to the antioxidant properties of PYR, other mechanisms of PYR stress-ameliorating effects have been proposed. These include an increase in sarcoplasmic reticular Ca2+ transport, improvement in mitochondrial function, increase in ATP concentration, or support of NADPH production to maintain the glutathione/glutathione disulfide (GSH/GSSG) redox potential (for review, see27,38). Another possible mechanism of PYR-induced protection is the modulation of cellular redox potential by decreasing the cytosolic NADH/NAD ​+ ​ratio.39

In our study, a single-dose PYR ingestion caused a greater increase in blood LA concentration after exercise at 90% V˙O2max compared with placebo.26 This result may reflect elevated blood bicarbonate concentration.20,26 It is possible that a higher LA concentration may also be caused by the reaction of PYR with accumulated NADH. In muscle cells, NADH is oxidized continuously by the malate-aspartate shuttle or by LDH.40 During exercise at a higher intensity, the rate of anaerobic glycolysis and the concentration of NADH in cytosol increase.41 Therefore, ingestion of PYR may not modify blood LA concentration at rest16 but may affect the redox state of muscle cells and accelerate LA production during exercise at higher power output (Fig. 3).26Fig. 3 Hypothetical metabolism of exogenous PYR during exercise at 90% V˙O2max. PYR – pyruvate; LA – lactate; LDH – lactate dehydrogenase; MCT – monocarboxylate transporter.

Fig. 3

6 Mechanisms of adaptation

The recognition of NAD+ as a multifunctional signaling molecule has been driven mainly by research in the field of exercise and nutrition. One of the key cell signaling candidates proposed is the NAD-dependent mitochondrial deacetylases family – sirtuins (SIRTs). SIRTs modulate many cellular processes, including energy metabolism, mitochondrial biogenesis, and protection against oxidative stress (these topics have been reviewed in detail elsewhere42, 43, 44).

Because NAD+ is a coenzyme of the reaction catalyzed by SIRTs, the activity of these enzymes increases when NAD+ concentration increases. By contrast, the expression follows a different pattern; that is, the enzyme expression is induced by an increase in the NADH/NAD+ ratio (predominantly a simultaneous decrease in NAD+ and increase in NADH concentrations).45 Physical exercise modulates the redox state of muscle cells according to the exercise intensity. During low or moderate exercise intensity, cytosolic NADH is continuously oxidized by the malate-aspartate shuttle, which controls the NADH/NAD ​+ ​ratio.40 At higher exercise intensity, the accumulation of cytosolic NADH can constrain glycolysis and thus limit performance.40 Therefore, a higher turnover via LDH is necessary to restore the NADH/NAD+ ratio. The modulation of the NADH/NAD+ ratio by exogenous PYR may impact histone deacetylase activity but only during exercise performed at intensities higher than the LA threshold.

7 PYR and neuroprotection

The brain is a highly energy-demanding organ, and its proper functioning depends on an adequate supply of energy substrates.46,47 As a source of energy, PYR has a positive effect in animal models of Alzheimer disease (AD).48, 49, 50 A diet enriched with PYR and β-hydroxybutyrate for 5 weeks, averaging ∼26 ​mg daily intake of substrates, improved cerebral energy metabolism in transgenic mice. This involved mitigating glycogen depletion and NAD(P)H autofluorescence.48 Subsequent study on PYR alone confirmed increased brain glycogen storages, and indicated elevation of energy metabolites, such as creatine, LA, and glutamate.49 Koivisto and colleagues49 demonstrated that long-term NaPYR supplementation (∼800 ​mg/kg/d for 2–6 months) increased exploratory behavior in both wild-type and AD transgenic mice, highlighting its effects on cognitive function.

In addition to its well-recognized function in energy metabolism, PYR may be an effective neuroprotector to reduce the rate of cognitive decline.51 A recent study reported that the intraperitoneal injection of ethyl pyruvate (EtPYR) promoted the expression of brain-derived neurotrophic factor (BDNF) by astrocytes and astrocyte transdifferentiation into oligodendrocytes, which suggested that PYR treatment may help to facilitate myelin sheath regeneration.52 Given that triggering BDNF expression in the brain is recognized as having neuroprotective effects,53 BDNF stimulation by PYR may have neuroprotective properties and improve cognitive performance.

PYR acts as both an antioxidant and anti-inflammatory compound, and may protect neurons from oxidative stress and neuroinflammation, both of which are associated with cognitive decline and neurodegenerative disorders.49,54 Systemic administration of PYR has been reported to have neuroprotective effects in animal models of brain injury,55 hypoglycemic cognitive impairment,56 ethanol-induced neurodegeneration,57 and age-dependent cognitive deficits in a mouse model of AD.50 The results of in vivo studies showing a neuroprotective effect of PYR are summarized in Table 2. In addition, in vitro studies have shown that PYR has protective effects against glutamate neurotoxicity,58 neuronal cell death induced by hydrogen peroxide,59 oxygen-glucose deprivation,60 and zinc-induced cortical neuronal death.61Table 2 Main results of PYR neuroprotective studies.

Table 2animals
model	intervention	administration	average pyruvate dose	period	pyruvate form	outcome	Ref. #	
closed head injury rats	acute	iv	0.9 mmoles/100 ​g	–	PYR	improved neurological outcome	62	
traumatic brain injury rats	acute	iv	infusion over 30 ​min of 1 ml/100 ​g 1 ​M	–	PYR	hippocampal neuron survival	63	
status epilepticus rats	acute	ip	250 ​mg/kg	–	PYR	hippocampal neuron lose prevented	64	
cortical contusion injury in rats	acute	ip	500 ​mg/kg
1 000 ​mg/kg
3 ​× ​1 000 ​mg/kg	–	NaPYR	attenuate cortical cell damage	55	
ischemic-middle cerebral artery occlusion rats	acute	ip	500 ​mg/kg	–	EtPYR	protective anti-inflammatory action	65	
focal ischemia
rats	acute	ip
iv	62.5–250 ​mg/kg	–	NaPYR	neuroprotective capacity in focal cerebral ischemia	66	
insulin-induced hypoglycemia rats	acute	ip	500 ​mg/kg	–	NaPYR	reduces the neuronal death and cognitive impairment	56	
ethanol injected C57Bl/6 mice	acute	sc	500 ​mg/kg	–	PYR	reduced neuronal cell loss in the
cortex and thalamus	57	
C57Bl/6J male mice	acute	ip	500 ​mg/kg	–	NaPYR	no effect in the passive avoidance task	49	
3 month old 3xTg-Alzheimer Disease mice model	chronic	ip	500 ​mg/kg	3× week per 9 months	PYR	counteract progression of AD-related cognitive deficits and neuronal loss	50	
cuprizone-induced demyelination mice model	chronic	ip	10 ​mg/kg	14 days	EtPYR	improved behavioural performance and promoted myelin regeneration	67	
cuprizone-induced demyelination mice model	chronic	ip	20 ​mg/kg	14 days	EtPYR	promoted astrocytes to phagocytized myelin debris for removing the harmful substances of myelin regeneration, BDNF and CNTF induction	52	
iv – intravenously; ip – intraperitoneally; sc – subcutaneously; PYR – pyruvate; NaPYR – sodium pyruvate; EtPYR - ethyl pyruvate; BDNF – brain-derived neurotrophic factor.

8 Future directions

Further research is warranted to elucidate the optimal timing, dosage, and form of PYR supplementation for maximizing its potential benefits on exercise performance, body composition, and metabolic health.

Deeper mechanistic studies are needed to unravel the molecular pathways underlying PYR's diverse effects on metabolism, cellular redox state, and exercise physiology. This includes investigating its interactions with key enzymes, signaling molecules, and metabolic pathways involved in energy production, antioxidant defense, and cellular signaling.

Conducting well-designed studies in specific populations, such as individuals with obesity, metabolic disorders, neurodegenerative diseases, or athletes, could provide valuable insights into the efficacy of PYR supplementation in diverse contexts.

Given the emerging role of gut microbiota in modulating host metabolism and health, investigating the impact of PYR supplementation on gut microbiota composition and function could provide novel insights into its metabolic effects and potential mechanisms of action.

9 Conclusions

PYR is an important compound in aerobic and anaerobic energy metabolism. PYR ingested before high-intensity exercise can affect power output. Prolonged supplementation, especially in combination with interval training, may induce adaptive changes in skeletal muscle metabolism and/or affect cognitive function through neuroprotective effects. It may be of interest to study the effects of PYR supplementation by focusing on the optimal timing, dosage, and form of PYR intake.

Submission statement

The manuscript has not been published previously, is not under consideration for publication elsewhere, and is approved by all authors. If accepted, it will not be published elsewhere, including electronically in the same form, in English or any other language, without the written consent of the copyright holder.

Authors' contributions

Robert A. Olek: Writing – original draft, Conceptualization. Sylwester Kujach: Writing – original draft. Zsolt Radak: Writing – review & editing.

Conflict of interest

Zsolt Radak is ​an editorial board member for Sports Medicine and Health Science and was not in the editorial review or the decision to publish this article. Otherwise authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
==== Refs
References

1 Mole P.A. Baldwin K.M. Terjung R.L. Holloszy J.O. Enzymatic pathways of pyruvate metabolism in skeletal muscle: adaptations to exercise Am J Physiol 224 1 1973 50 54 10.1152/ajplegacy.1973.224.1.50 4683308
2 Gray L.R. Tompkins S.C. Taylor E.B. Regulation of pyruvate metabolism and human disease Cell Mol Life Sci 71 14 2014 2577 2604 10.1007/s00018-013-1539-2 24363178
3 Stanko R.T. Tietze D.L. Arch J.E. Body composition, energy utilization, and nitrogen metabolism with a 4.25-MJ/d low-energy diet supplemented with pyruvate Am J Clin Nutr 56 4 1992 630 635 10.1093/ajcn/56.4.630 1414961
4 Stanko R.T. Tietze D.L. Arch J.E. Body composition, energy utilization, and nitrogen metabolism with a severely restricted diet supplemented with dihydroxyacetone and pyruvate Am J Clin Nutr 55 4 1992 771 776 10.1093/ajcn/55.4.771 1550057
5 Stanko R.T. Reynolds H.R. Lonchar K.D. Arch J.E. Plasma lipid concentrations in hyperlipidemic patients consuming a high-fat diet supplemented with pyruvate for 6 wk Am J Clin Nutr 56 5 1992 950 954 10.1093/ajcn/56.5.950 1345038
6 Stanko R.T. Reynolds H.R. Hoyson R. Janosky J.E. Wolf R. Pyruvate supplementation of a low-cholesterol, low-fat diet: effects on plasma lipid concentrations and body composition in hyperlipidemic patients Am J Clin Nutr 59 2 1994 423 427 10.1093/ajcn/59.2.423 8310996
7 Kalman D. Colker C.M. Wilets I. Roufs J.B. Antonio J. The effects of pyruvate supplementation on body composition in overweight individuals Nutrition 15 5 1999 337 340 10.1016/s0899-9007(99)00034-9 10355844
8 Koh-Banerjee P.K. Ferreira M.P. Greenwood M. Effects of calcium pyruvate supplementation during training on body composition, exercise capacity, and metabolic responses to exercise Nutrition 21 3 2005 312 319 10.1016/j.nut.2004.06.026 15797672
9 Onakpoya I. Hunt K. Wider B. Ernst E. Pyruvate supplementation for weight loss: a systematic review and meta-analysis of randomized clinical trials Crit Rev Food Sci Nutr 54 1 2014 17 23 10.1080/10408398.2011.565890 24188231
10 Stone M.H. Sanborn K. Smith L.L. Effects of in-season (5 weeks) creatine and pyruvate supplementation on anaerobic performance and body composition in American football players Int J Sport Nutr 9 2 1999 146 165 10.1123/ijsn.9.2.146 10362452
11 Ostojic S.M. Ahmetovic Z. The effect of 4 weeks treatment with a 2-gram daily dose of pyruvate on body composition in healthy trained men Int J Vitam Nutr Res 79 3 2009 173 179 10.1024/0300-9831.79.3.173 20209468
12 Kalman D. Colker C.M. Stark R. Minsch A. Wilets I. Antonio J. Effect of pyruvate supplementation on body composition and mood Curr Ther Res Clin Exp 59 11 1998 793 802 10.1016/S0011-393X(98)85105-9
13 Stanko R.T. Robertson R.J. Galbreath R.W. Reilly J.J. Jr. Greenawalt K.D. Goss F.L. Enhanced leg exercise endurance with a high-carbohydrate diet and dihydroxyacetone and pyruvate J Appl Physiol (1985) 69 5 1990 1651 1656 10.1152/jappl.1990.69.5.1651 2272957
14 Stanko R.T. Robertson R.J. Spina R.J. Reilly J.J. Jr. Greenawalt K.D. Goss F.L. Enhancement of arm exercise endurance capacity with dihydroxyacetone and pyruvate J Appl Physiol (1985) 68 1 1990 119 124 10.1152/jappl.1990.68.1.119 2312449
15 Ebersole K.T. Stout J.R. Eckerson J.M. Housh T.J. Evetovich T.K. Smith D.B. The effect of pyruvate supplementation on critical power J Strength Condit Res 14 2 2000 132 134 10.1519/00124278-200005000-00002
16 Morrison M.A. Spriet L.L. Dyck D.J. Pyruvate ingestion for 7 days does not improve aerobic performance in well-trained individuals J Appl Physiol (1985) 89 2 2000 549 556 10.1152/jappl.2000.89.2.549 10926637
17 Maughan R.J. Burke L.M. Dvorak J. IOC consensus statement: dietary supplements and the high-performance athlete Int J Sport Nutr Exerc Metabol 28 2 2018 104 125 10.1123/ijsnem.2018-0020
18 Yang Y.P. Qiu J.Q. Wang M.Y. Effects of sodium pyruvate supplementation on repeated sprint exercise performance and recovery in male college soccer players: a randomized controlled trial Ann Palliat Med 11 2 2022 598 610 10.21037/apm-21-3862 35249338
19 Waterhouse C. Keilson J. Cori cycle activity in man J Clin Invest 48 12 1969 2359 2366 10.1172/JCI106202 5355347
20 Olek R.A. Luszczyk M. Kujach S. Single pyruvate intake induces blood alkalization and modification of resting metabolism in humans Nutrition 31 3 2015 466 474 10.1016/j.nut.2014.09.012 25701336
21 LaNoue K. Nicklas W.J. Williamson J.R. Control of citric acid cycle activity in rat heart mitochondria J Biol Chem 245 1 1970 102 111 4312474
22 Constantin-Teodosiu D. Simpson E.J. Greenhaff P.L. The importance of pyruvate availability to PDC activation and anaplerosis in human skeletal muscle Am J Physiol 276 3 1999 E472 E478 10.1152/ajpendo.1999.276.3.E472 10070012
23 Poole R.C. Halestrap A.P. Transport of lactate and other monocarboxylates across mammalian plasma membranes Am J Physiol 264 4 Pt 1 1993 C761 C782 10.1152/ajpcell.1993.264.4.C761 8476015
24 Zhou F.Q. Pyruvate in the correction of intracellular acidosis: a metabolic basis as a novel superior buffer Am J Nephrol 25 1 2005 55 63 10.1159/000084141 15731550
25 Mongan P.D. Fontana J.L. Chen R. Bunger R. Intravenous pyruvate prolongs survival during hemorrhagic shock in swine Am J Physiol 277 6 1999 H2253 H2263 10.1152/ajpheart.1999.277.6.H2253 10600844
26 Olek R.A. Kujach S. Wnuk D. Laskowski R. Single sodium pyruvate ingestion modifies blood acid-base status and post-exercise lactate concentration in humans Nutrients 6 5 2014 1981 1992 10.3390/nu6051981 24841105
27 Mallet R.T. Olivencia-Yurvati A.H. Bunger R. Pyruvate enhancement of cardiac performance: cellular mechanisms and clinical application Exp Biol Med (Maywood) 243 2 2018 198 210 10.1177/1535370217743919 29154687
28 Andres S. Ziegenhagen R. Trefflich I. Creatine and creatine forms intended for sports nutrition Mol Nutr Food Res 61 6 2017 10.1002/mnfr.201600772 10.1002/mnfr.201600772
29 Kreider R.B. Jäger R. Purpura M. Bioavailability, efficacy, safety, and regulatory status of creatine and related compounds: a critical review Nutrients 14 5 2022 1035 10.3390/nu14051035 35268011
30 Holleman A.F. Notice sur l'action de l'eau oxygénée sur les acides α-cétoniques et sur les dicétones 1. 2 Recueil des Travaux Chimiques des Pays-Bas et de la Belgique 23 5 1904 169 172 10.1002/recl.19040230504
31 Olek R.A. Antosiewicz J. Popinigis J. Gabbianelli R. Fedeli D. Falcioni G. Pyruvate but not lactate prevents NADH-induced myoglobin oxidation Free Radic Biol Med 38 11 2005 1484 1490 10.1016/j.freeradbiomed.2005.02.018 15890622
32 Ziolkowski W. Wierzba T.H. Kaczor J.J. Intravenous sodium pyruvate protects against cerulein-induced acute pancreatitis Pancreas 37 2 2008 238 239 10.1097/MPA.0b013e31816726e7 18665097
33 Olek R.A. Ziolkowski W. Kaczor J.J. Wierzba T.H. Antosiewicz J. Higher hypochlorous acid scavenging activity of ethyl pyruvate compared to its sodium salt Biosci Biotechnol Biochem 75 3 2011 500 504 10.1271/bbb.100728 21389621
34 Zhang X.M. Deng H. Tong J.D. Pyruvate-enriched oral rehydration solution improves glucometabolic disorders in the kidneys of diabetic db/db mice J Diabetes Res 2020 2020 2817972 10.1155/2020/2817972
35 Vasquez-Vivar J. Denicola A. Radi R. Augusto O. Peroxynitrite-mediated decarboxylation of pyruvate to both carbon dioxide and carbon dioxide radical anion Chem Res Toxicol 10 7 1997 786 794 10.1021/tx970031g 9250413
36 Dobsak P. Courderot-Masuyer C. Zeller M. Antioxidative properties of pyruvate and protection of the ischemic rat heart during cardioplegia J Cardiovasc Pharmacol 34 5 1999 651 659 10.1097/00005344-199911000-00005 10547080
37 Fedeli D. Falcioni G. Olek R.A. Protective effect of ethyl pyruvate on msP rat leukocytes damaged by alcohol intake J Appl Toxicol 27 6 2007 561 570 10.1002/jat.1236 17351912
38 Hassel B. Pyruvate carboxylation in neurons J Neurosci Res 66 5 2001 755 762 10.1002/jnr.10044 11746399
39 Park J.W. Chun Y.S. Kim M.S. Park Y.C. Kwak S.J. Park S.C. Metabolic modulation of cellular redox potential can improve cardiac recovery from ischemia-reperfusion injury Int J Cardiol 65 2 1998 139 147 10.1016/s0167-5273(98)00117-x 9706808
40 Spriet L.L. Howlett R.A. Heigenhauser G.J. An enzymatic approach to lactate production in human skeletal muscle during exercise Med Sci Sports Exerc 32 4 2000 756 763 10.1097/00005768-200004000-00007 10776894
41 Schantz P.G. Plasticity of human skeletal muscle with special reference to effects of physical training on enzyme levels of the NADH shuttles and phenotypic expression of slow and fast myofibrillar proteins Acta Physiol Scand Suppl 558 1986 1 62 2950727
42 Radak Z. Suzuki K. Posa A. Petrovszky Z. Koltai E. Boldogh I. The systemic role of SIRT1 in exercise mediated adaptation Redox Biol 35 2020 101467 10.1016/j.redox.2020.101467
43 Ji L.L. Yeo D. Maintenance of NAD+ homeostasis in skeletal muscle during aging and exercise Cells 11 4 2022 710 10.3390/cells11040710 35203360
44 Zhou L. Pinho R. Gu Y. Radak Z. The role of SIRT3 in exercise and aging Cells 11 16 2022 2596 10.3390/cells11162596 36010672
45 Gambini J. Gomez-Cabrera M.C. Borras C. Free [NADH]/[NAD(+)] regulates sirtuin expression Arch Biochem Biophys 512 1 2011 24 29 10.1016/j.abb.2011.04.020 21575591
46 Ide K. Schmalbruch I.K. Quistorff B. Horn A. Secher N.H. Lactate, glucose and O2 uptake in human brain during recovery from maximal exercise J Physiol 522 Pt 1 2000 159 164 10.1111/j.1469-7793.2000.t01-2-00159.xm 10618160
47 Dalsgaard M.K. Ide K. Cai Y. Quistorff B. Secher N.H. The intent to exercise influences the cerebral O(2)/carbohydrate uptake ratio in humans J Physiol 540 Pt 2 2002 681 689 10.1113/jphysiol.2001.013062 11956354
48 Zilberter M. Ivanov A. Ziyatdinova S. Dietary energy substrates reverse early neuronal hyperactivity in a mouse model of Alzheimer's disease J Neurochem 125 1 2013 157 171 10.1111/jnc.12127 23241062
49 Koivisto H. Leinonen H. Puurula M. Chronic pyruvate supplementation increases exploratory activity and brain energy reserves in young and middle-aged mice Front Aging Neurosci 8 2016 41 10.3389/fnagi.2016.00041 27014054
50 Isopi E. Granzotto A. Corona C. Pyruvate prevents the development of age-dependent cognitive deficits in a mouse model of Alzheimer's disease without reducing amyloid and tau pathology Neurobiol Dis 81 2015 214 224 10.1016/j.nbd.2014.11.013 25434488
51 Zilberter Y. Gubkina O. Ivanov A.I. A unique array of neuroprotective effects of pyruvate in neuropathology Front Neurosci 9 2015 17 10.3389/fnins.2015.00017 25741230
52 He Y. An J. Yin J.J. Ethyl pyruvate-derived transdifferentiation of astrocytes to oligodendrogenesis in cuprizone-induced demyelinating model Neurotherapeutics 18 1 2021 488 502 10.1007/s13311-020-00947-x 33140235
53 Wang J. Zhang S. Ma H. Chronic intermittent hypobaric hypoxia pretreatment ameliorates ischemia-induced cognitive dysfunction through activation of ERK1/2-CREB-BDNF pathway in anesthetized mice Neurochem Res 42 2 2017 501 512 10.1007/s11064-016-2097-4 27822668
54 Kao K.K. Fink M.P. The biochemical basis for the anti-inflammatory and cytoprotective actions of ethyl pyruvate and related compounds Biochem Pharmacol 80 2 2010 151 159 10.1016/j.bcp.2010.03.007 20230800
55 Fukushima M. Lee S.M. Moro N. Hovda D.A. Sutton R.L. Metabolic and histologic effects of sodium pyruvate treatment in the rat after cortical contusion injury J Neurotrauma 26 7 2009 1095 1110 10.1089/neu.2008.0771 19594384
56 Suh S.W. Aoyama K. Matsumori Y. Liu J. Swanson R.A. Pyruvate administered after severe hypoglycemia reduces neuronal death and cognitive impairment Diabetes 54 5 2005 1452 1458 10.2337/diabetes.54.5.1452 15855333
57 Ullah N. Naseer M.I. Ullah I. Kim T.H. Lee H.Y. Kim M.O. Neuroprotective profile of pyruvate against ethanol-induced neurodegeneration in developing mice brain Neurol Sci 34 12 2013 2137 2143 10.1007/s10072-013-1350-8 23494720
58 Miao Y. Qiu Y. Lin Y. Miao Z. Zhang J. Lu X. Protection by pyruvate against glutamate neurotoxicity is mediated by astrocytes through a glutathione-dependent mechanism Mol Biol Rep 38 5 2011 3235 3242 10.1007/s11033-010-9998-0 20182801
59 Nakamichi N. Kambe Y. Oikawa H. Protection by exogenous pyruvate through a mechanism related to monocarboxylate transporters against cell death induced by hydrogen peroxide in cultured rat cortical neurons J Neurochem 93 1 2005 84 93 10.1111/j.1471-4159.2005.02999.x 15773908
60 Ryou M.G. Choudhury G.R. Winters A. Xie L. Mallet R.T. Yang S.H. Pyruvate minimizes rtPA toxicity from in vitro oxygen-glucose deprivation and reoxygenation Brain Res 1530 2013 66 75 10.1016/j.brainres.2013.07.029 23891792
61 Sheline C.T. Behrens M.M. Choi D.W. Zinc-induced cortical neuronal death: contribution of energy failure attributable to loss of NAD(+) and inhibition of glycolysis J Neurosci 20 9 2000 3139 3146 10.1523/JNEUROSCI.20-09-03139.2000 10777777
62 Zlotnik A. Gurevich B. Cherniavsky E. The contribution of the blood glutamate scavenging activity of pyruvate to its neuroprotective properties in a rat model of closed head injury Neurochem Res 33 6 2008 1044 1050 10.1007/s11064-007-9548-x 18080187
63 Zlotnik A. Sinelnikov I. Gruenbaum B.F. Effect of glutamate and blood glutamate scavengers oxaloacetate and pyruvate on neurological outcome and pathohistology of the hippocampus after traumatic brain injury in rats Anesthesiology 116 1 2012 73 83 10.1097/ALN.0b013e31823d7731 22129535
64 Carvalho A.S. Torres L.B. Persike D.S. Neuroprotective effect of pyruvate and oxaloacetate during pilocarpine induced status epilepticus in rats Neurochem Int 58 3 2011 385 390 10.1016/j.neuint.2010.12.014 21185899
65 Kim J.B. Yu Y.M. Kim S.W. Lee J.K. Anti-inflammatory mechanism is involved in ethyl pyruvate-mediated efficacious neuroprotection in the postischemic brain Brain Res 1060 1-2 2005 188 192 10.1016/j.brainres.2005.08.029 16226231
66 Yi J.S. Kim T.Y. Kyu Kim D. Koh J.Y. Systemic pyruvate administration markedly reduces infarcts and motor deficits in rat models of transient and permanent focal cerebral ischemia Neurobiol Dis 26 1 2007 94 104 10.1016/j.nbd.2006.12.007 17261368
67 He Y. An J. Yin J.J. Ethyl pyruvate enhances spontaneous remyelination by targeting microglia phagocytosis Int Immunopharm 77 2019 105929 10.1016/j.intimp.2019.105929
